Weal and woe of interleukin-18 in the T cell therapy of cancer
Chimeric antigen receptor (CAR) T cell therapy of solid cancer remains below expectations; adding cytokine help through IL-18 has shown remarkable efficacy in first clinical trials. As IL-18 is also a powerful driver of hyperinflammatory conditions, we discuss to what extent unleashing IL-18 is a do...
Saved in:
Main Authors: | Christoph Kessel, Hinrich Abken, Claudia Rossig |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/1/e010545.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Engineered T Cells for the Adoptive Therapy of B-Cell Chronic Lymphocytic Leukaemia
by: Philipp Koehler, et al.
Published: (2012-01-01) -
Water woes: the institutional challenges in achieving SDG 6
by: Jaivime Evaristo, et al.
Published: (2023-11-01) -
The role of interleukin-6 classic and trans-signaling and interleukin-11 classic signaling in gastric cancer cells
by: Josephine Runge, et al.
Published: (2024-08-01) -
Role of Interleukin-18 in Modulation of Oral Carcinoma Cell Proliferation
by: Athip Nilkaeo, et al.
Published: (2006-01-01) -
Role of Interleukin-18 in Modulation of Oral Carcinoma Cell Proliferation
Published: (2006-01-01)